References

pharmjournal

Разработка и регистрация лекарственных средств

Drug development & registration

2305-20662658-5049

LLC «CPHA»

pharmjournal-227

Research Article

БИОТЕХНОЛОГИЯ

BIOTECHNOLOGY

РЕКОМБИНАНТНЫЕ АНТИГЕНЫ ВАКЦИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ПАПИЛЛОМЫ (ОБЗОР)

THE RECOMBINANT ANTIGENS FOR VACCINES FOR THE TREATMENT OF PAPILLOMAVIRUS (REVIEW)

Жученко

М. А.

Zhuchenko

M. A.

noemail@neicon.ru

Государственный научный центр Российской Федерации ФГУП «Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов» (ФГУП «ГосНИИгенетика»)Scientific Center of Russian Federation «Research Institute for Genetics and Selection of Industrial Microorganisms»

2016

09012019

019298

2019

Жученко М.А.

Zhuchenko M.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.pharmjournal.ru/jour/article/view/227

Профилактика заболеваний, ассоциированных с вирусом папилломы человека, на сегодняшний день осуществляется двумя лицензированными вакцинами - «Гардасил» и «Церварикс», содержащими в качестве антигена вирусоподобные частицы на основе главного капсидного белка L1. Свойства L1 не позволяют обеспечить защиту от всех патогенных штаммов ВПЧ, демонстрируют низкую эффективность при вакцинации пациентов среднего и пожилого возрастов и не являются терапевтически эффективными. Следующее поколение вакцин, содержащих консервативные эпитопы минорного белка L2, а также онкобелки Е6 и Е7, обещают предоставить широкую защиту от всех ВПЧ, препятствуя как возникновению, так и распространению кожных новообразований.

Two licensed vaccines Gardasil and Cervarix, containing main capsid protein L1 virus-like particles antigen, are used for prevention of diseases associated with human papilloma virus. L1 cannot provide protection against all pathogenic strains of HPV, shows low efficacy in middle and old age vaccinated patients, and are not therapeutically effective. The next generation of vaccines that contain minor protein L2 conserved epitopes as well as oncoproteins E6 and E7 promise to provide broad protection against all HPV, and prevent the emergence and spread of skin lesions.

ВПЧБТШвакцина

HPVVLPL1L2E6E7HSPvaccine

References1

А. Ройт. Иммунология. - М.: Мир, 2000. C. 15.

Н.В. Медуницын. Вакцинология. - М.: Триада-Х, 2004. Ч. 1.

R.T. Kenney, R. Edelman, M.M. Levine, J.B. Kaper, R. Rappuoli. In New Generation Vaccines. 2nd ed. - N.Y.; Basel: Marcel Dekker, 1997. P. 213-223.

M. Liniger, A. Zuniga, H.Y. Naim. Use of viral vectors for the development of vaccines // Expert Rev. Vaccines. 2007. V. 6. № 2. P. 255-266.

I.H. Frazer. Prevention of cervical cancer through papillomavirus vaccination // Nature Rev. Immunol. 2004. V. 4. P. 46-54.

The Nobel Prize in Physiology or Medicine 2008. URL: http://www.nobelprize.org/nobel_prizes/medicine/laureates/2008/ (дата обращения 23.01.2016).

V. Cogliano, R. Baan, K. Straif, Y. Grosse, B. Secretan. Carcinogenicity of human papillomaviruses // Lancet Oncol. 2005. V. 6. P. 204.

F. Fehrmann, L.A. Laimins. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation // Oncogene. 2003. V. 22. № 33. P. 5201-5207.

В.А. Исаков, Д. К. Ермоленко, Ф. Р. Кутуева. Использование циклоферона в терапии папилломавирусной инфекции. Рекомендации для врачей. - СПб.; Великий Новгород: Тактик-Студио, 2007. C. 64.

X.S. Chen, G. Casini, S.C. Harrison, R.L. Garcea. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1 // J. Mol. Biol. 2001. V. 307. № 1. P. 173-182.

J. Zhou, X.Y. Sun, D.J. Stenzel, I.H. Frazer. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles // Virology. 1991. V. 185. P. 251-257.

X.S. Chen, R.L. Garcea, I. Goldberg, G. Casini, S.C. Harrison. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16 // Mol. Cell. 2000. V. 5. № 3. P. 557-567.

R.B. Roden, R. Kirnbauer, A.B. Jenson, D.R. Lowy, J.T. Schiller. Interaction of papillomaviruses with the cell surface // J. Virol. 1994. V. 68. № 11. P. 7260-7266.

V.A. Olcese, Y. Chen, R. Schlegel, H. Yuan. Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope // Microbiol. 2004. V. 4. P. 29.

J.A. Suzich, S.J. Ghim, F.J. Palmer-Hill, W.I. White, J.K. Tamura. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas // Proc. Natl. Acad. Sci. 1995. V. 92. № 25. P. 11553-11557.

F. Breitburd, R. Kirnbauer, N.L. Hubbert, B. Nonnenmacher, G. Trin-Dinh-Desmarquet. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection // J. Virol. 1995. V. 69. № 6. P. 3959-3963.

F.T. Cutts, S. Franceschi, S. Goldie, X. Castellsague, S. de Sanjose. Human papillomavirus and HPV vaccines: a review // Bull. World Health Organ. 2007. V. 85. № 9. P. 719-726.

L.L. Villa, K.A. Ault, A.R. Giuliano, R.L. Costa, C.A. Petta. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 // Vaccine. 2006. V. 7. № 27-28. P. 5571-5583.

D.M. Harper, E.L. Franco, C.M. Wheeler, A.B. Moscicki, B. Romanowski. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial // Lancet. 2006. V. 367. № 9518. P. 1247-1255.

L.L. Villa, R.L.R. Costa, C.A. Petta, R.P. Andrade, J. Paavonen. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of followup // Br. J. Cancer. 2006. V. 95. № 11. P. 1459-1466.

Vaccines And Related Biological Products Advisory Committee Meeting. URL: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222b-index.htm (дата обращения 23.01.2016).

R. Kirnbauer, J. Taub, H. Greenstone, R. Roden, M. Dürst. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles // J. Virol. 1993. V. 67. № 12. P. 6929-6936.

S.C. Holmgren, N.A. Patterson, M.A. Ozbun, P.F. Lambert. The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle // J. Virol. 2005. V. 79. № 7. P. 3938-3948.

M.E. Hagensee, N. Yaegashi, D.A. Galloway. Selfassembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins // J. Virol. 1993. V. 67. № 1. P. 315-322.

N. Kämper, P.M. Day, T. Nowak, H.C. Selinka, L. Florin. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes // J. Virol. 2006. V. 80. № 2. P. 759-768.

J.M. Gaukroger, L.M. Chandrachud, B.W. O'Neil, G.J. Grindlay, G. Knowles, M.S. Campo. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies // J. Gen. Virol. 1996. V. 77. № 7. P. 1577-1583.

M.E. Embers, L.R. Budgeon, T.D. Culp, C.A. Reed, M.D. Pickel, N.D. Christensen. Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins // Vaccine. 2004. V. 22. № 5-6. P. 670-680.

N.D. Christensen, J.W. Kreider, N.C. Kan, S.L. DiAngelo. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes // Virology. 1991. V. 181. № 2. P. 572-579.

Y.L. Lin, L.A. Borenstein, R. Selvakumar, R. Ahmed, F.O. Wettstein. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus // Virology. 1992. V. 187. № 2. P. 612-619.

L.M. Chandrachud, G.J. Grindlay, G.M. McGarvie, B.W. O'Neil, E.R. Wagner. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4 // Virology. 1995. V. 211. № 1. P. 204-208.

C.J. Lacey, H.S. Thompson, E.F. Monteiro, T. O'Neill, M.L. Davies. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts // J. Infect. Dis. 1999. V. 179. № 3. P. 612-618.

K. Kawana, H. Yoshikawa, Y. Taketani, K. Yoshiike, T. Kanda. Common Neutralization Epitope in Minor Capsid Protein L2 of Human Papillomavirus Types 16 and 6 // J. Virol. 1999. V. 73. № 7. P. 6188-6190.

Human Papillomaviruses. URL: http://monographs. iarc.fr/ENG/Monographs/vol90/mono90.pdf (дата обращения 23.01.2016).

M. Rolfe, P. Beer-Romero, S. Glass, J. Eckstein, I. Berdo. Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitinconjugating enzyme UBC4 and E6-associated protein (E6AP) // Proc. Natl. Acad. Sci. USA. 1995. V. 92. № 8. P. 3264-3268.

K. Münger, B.A. Werness, № Dyson, W.C. Phelps, E. Harlow, P.M. Howley. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product // EMBO J. 1989. V. 8. № 13. P. 4099-4105.

K. Münger, W.C. Phelps, V. Bubb, P.M. Howley, R. Schlegel. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes // J. Virol. 1989. V. 63. № 10. P. 4417-4421.

O. Ohlenschläger, T. Seiboth, H. Zengerling, L. Briese, A. Marchanka, R. Ramachandran. Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7 // Oncogene. 2006. V. 25. № 44. P. 5953-5959.

K. Münger, J.R. Basile, S. Duensing, A. Eichten, S.L. Gonzalez. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein // Oncogene. 2001. V. 20. № 54. P. 7888-7898.

The authors declare that there are no conflicts of interest present.